The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Therapies for non-alcoholic fatty liver disease: A 2022 update
World J Hepatol. 2022 Sep 27;14(9):1718-1729. doi: 10.4254/wjh.v14.i9.1718.
1Department of Internal Medicine, Cleveland Clinic Foundation, Cleveland, OH 44195, United States. shenk2@ccf.org.
2Department of Internal Medicine, Cleveland Clinic Foundation, Cleveland, OH 44195, United States.
3Department of Gastroenterology and Hepatology, Cleveland Clinic Foundation, Cleveland, OH 44195, United States.
Abstract
The incidence of non-alcoholic fatty liver disease (NAFLD) is rapidly increasing and lifestyle interventions to treat this disease by addressing the underlying metabolic syndrome are often limited. Many pharmacological interventions are being studied to slow or even reverse NAFLD progression. This review for hepatologists aims to provide an updated understanding of the pathogenesis of NAFLD, current recommended therapies, and the most promising treatment options that are currently under development.